These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10073054)

  • 21. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of mumps in Quebec, 1970-1995.
    De Serres G; Boulianne N; Bussières N; Pouliot B; Marin-Lira A
    Can Commun Dis Rep; 1997 Jan; 23(2):9-13. PubMed ID: 9136223
    [No Abstract]   [Full Text] [Related]  

  • 23. Coverage of MMR vaccine.
    Begg N; Handford S
    Lancet; 1989 Dec 23-30; 2(8678-8679):1533. PubMed ID: 2574812
    [No Abstract]   [Full Text] [Related]  

  • 24. [Is a second dose of the triple viral vaccine necessary?].
    Echevarría JM; de Ory F
    Med Clin (Barc); 1997 Jun; 109(5):196-7. PubMed ID: 9289545
    [No Abstract]   [Full Text] [Related]  

  • 25. Japanese scientists plan MMR alternative.
    Chou IH
    Nat Med; 2003 Nov; 9(11):1337. PubMed ID: 14595415
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
    Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
    Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measles lessons learned.
    Scott G
    Nurs Stand; 1996 Jul; 10(44):13. PubMed ID: 8850749
    [No Abstract]   [Full Text] [Related]  

  • 28. MMR vaccine: combined or single antigens?
    Kassianos G
    Int J Clin Pract; 2001 Dec; 55(10):656-7. PubMed ID: 11777286
    [No Abstract]   [Full Text] [Related]  

  • 29. The mighty MMR.
    Smith S
    Community Outlook; 1988 Sep; ():8-9. PubMed ID: 3197416
    [No Abstract]   [Full Text] [Related]  

  • 30. [A seroconversion study of the measles component of the MMR vaccine in adolescents of the town of Sabrosa].
    Gonçalves G; Tavares F; de Andrade HR
    Acta Med Port; 1998 Dec; 11(12):1079-84. PubMed ID: 10192981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MMR vaccine debate.
    Community Nurse; 1998 Oct; 4(9):12-3. PubMed ID: 10326363
    [No Abstract]   [Full Text] [Related]  

  • 32. Are vaccination rates higher if providers receive free vaccines and follow contraindication guidelines?
    Zimmerman RK; Mieczkowski TA; Michel M
    Fam Med; 1999 May; 31(5):317-23. PubMed ID: 10407708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measles immunization in HIV-infected children. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Pediatric AIDS.
    Pediatrics; 1999 May; 103(5 Pt 1):1057-60. PubMed ID: 10224192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MMR immunisation: what advice should we give to parents?
    Rose V
    Prof Care Mother Child; 1998; 8(3):58-9. PubMed ID: 9814351
    [No Abstract]   [Full Text] [Related]  

  • 35. Measles-mumps-rubella immunisation, autism and inflammatory bowel disease: update.
    Amin J; Wong M
    Commun Dis Intell; 1999 Aug; 23(8):222. PubMed ID: 10497836
    [No Abstract]   [Full Text] [Related]  

  • 36. Gender differences in the reactogenicity of measles-mumps-rubella vaccine.
    Shohat T; Green MS; Nakar O; Ballin A; Duvdevani P; Cohen A; Shohat M
    Isr Med Assoc J; 2000 Mar; 2(3):192-5. PubMed ID: 10774264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mumps in 1997].
    Zabicka J
    Przegl Epidemiol; 1999; 53(1-2):41-4. PubMed ID: 10402848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization status of children born to human immunodeficiency virus (HIV)-infected mothers in two Texas cities.
    Schulte JM; Burkham S; Squires JE; Doran T; Hamaker DW; Pelosi J; Graper J; Davis R; Caldwell MB
    South Med J; 2000 Jan; 93(1):48-52. PubMed ID: 10653065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccination of children in 1999].
    Levy J
    Rev Med Brux; 1999 Sep; 20(4):A317-20. PubMed ID: 10523915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.